246 related articles for article (PubMed ID: 36831375)
1. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
[TBL] [Abstract][Full Text] [Related]
2. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
3. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
Ren L; Leisegang M; Deng B; Matsuda T; Kiyotani K; Kato T; Harada M; Park JH; Saloura V; Seiwert T; Vokes E; Agrawal N; Nakamura Y
Oncoimmunology; 2019; 8(4):e1568813. PubMed ID: 30906664
[TBL] [Abstract][Full Text] [Related]
4. Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.
Kato T; Matsuda T; Ikeda Y; Park JH; Leisegang M; Yoshimura S; Hikichi T; Harada M; Zewde M; Sato S; Hasegawa K; Kiyotani K; Nakamura Y
Oncotarget; 2018 Feb; 9(13):11009-11019. PubMed ID: 29541393
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
6. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
7. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract][Full Text] [Related]
8. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
10. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.
Okada M; Shimizu K; Nakazato H; Yamasaki S; Fujii SI
Mol Ther Methods Clin Dev; 2023 Jun; 29():541-555. PubMed ID: 37359417
[TBL] [Abstract][Full Text] [Related]
11. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
12. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
[TBL] [Abstract][Full Text] [Related]
13. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
Hung SI; Chu MT; Hou MM; Lee YS; Yang CK; Chu SY; Liu FY; Hsu HC; Pao SC; Teng YC; Chen CB; Chao A; Chung WH; Chang JW; Lai CH
Biomed Pharmacother; 2023 Dec; 169():115928. PubMed ID: 38011788
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
15. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
Liu S; Matsuzaki J; Wei L; Tsuji T; Battaglia S; Hu Q; Cortes E; Wong L; Yan L; Long M; Miliotto A; Bateman NW; Lele SB; Chodon T; Koya RC; Yao S; Zhu Q; Conrads TP; Wang J; Maxwell GL; Lugade AA; Odunsi K
J Immunother Cancer; 2019 Jun; 7(1):156. PubMed ID: 31221207
[TBL] [Abstract][Full Text] [Related]
16. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
[TBL] [Abstract][Full Text] [Related]
17. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
Peri A; Greenstein E; Alon M; Pai JA; Dingjan T; Reich-Zeliger S; Barnea E; Barbolin C; Levy R; Arnedo-Pac C; Kalaora S; Dassa B; Feldmesser E; Shang P; Greenberg P; Levin Y; Benedek G; Levesque MP; Adams DJ; Lotem M; Wilmott JS; Scolyer RA; Jönsson GB; Admon A; Rosenberg SA; Cohen CJ; Niv MY; Lopez-Bigas N; Satpathy AT; Friedman N; Samuels Y
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651586
[TBL] [Abstract][Full Text] [Related]
18. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
Wolf SP; Anastasopoulou V; Drousch K; Diehl MI; Engels B; Yew PY; Kiyotani K; Nakamura Y; Schreiber K; Schreiber H; Leisegang M
Clin Cancer Res; 2024 Apr; 30(8):1642-1654. PubMed ID: 38190111
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.
Zhou W; Yu J; Li Y; Wang K
Exp Hematol Oncol; 2022 Nov; 11(1):100. PubMed ID: 36384590
[TBL] [Abstract][Full Text] [Related]
20. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
